The 7-gene signature loses predictive ability in the transplantation setting. (A) Kaplan-Meier plot showing the PFS of patients who received PAD within the HOVON-65/GMMG-HD4 study (n = 143) before ASCT and who were predicted to benefit from bortezomib-based therapy (n = 58; broken line) or from RD therapy (n = 85; solid line) by the 7-gene signature after training in PADIMAC. The P value and HR are those obtained from Cox regression analysis. (B) Kaplan-Meier plot showing the OS of patients who received PAD within the HOVON-65/GMMG-HD4 study (n = 143) before ASCT and who were predicted to benefit from bortezomib-based therapy (n = 58; broken line) or RD therapy (n = 85; solid line) by the 7-gene signature after training in PADIMAC. The P value and HR are those obtained from Cox regression analysis.